Sokka T, Möttönen T, Hannonen P
Department of Medicine, Jyväskylä Central Hospital, Finland.
Scand J Rheumatol. 1999;28(5):282-7. doi: 10.1080/03009749950155463.
To describe mortality in a cohort of early RA patients treated from the onset with disease-modifying antirheumatic drugs (DMARDs) according to the 'sawtooth' strategy.
A total of 135 early RA patients were followed up for 8-14 years or until death. Causes of death were checked on the death certificates and in patient files. Standardized mortality ratio (SMR) was calculated. Results. A total of 25 (14F, 11M) patients died during the 1422 person-years of follow-up. The SMR (95%CI) was 1.28 (0.83-1.89); 1.69 (0.92-2.82) for women and 0.98 (0.49-1.74) for men. In five cases death was closely related to RA. No one died from amyloidosis. Not a single death was caused by DMARDs in spite of extensive use of these drugs. Patient's age at the start was the only statistically significant predictor for death.
Despite active treatment with available DMARDs, RA seems still to be a fatal disease in a proportion of cases.
描述一组根据“锯齿”策略从发病起就接受改善病情抗风湿药物(DMARDs)治疗的早期类风湿关节炎(RA)患者的死亡率。
共对135例早期RA患者进行了8至14年的随访或直至死亡。通过死亡证明和患者病历核查死亡原因。计算标准化死亡率(SMR)。结果。在1422人年的随访期间,共有25例(14例女性,11例男性)患者死亡。SMR(95%可信区间)为1.28(0.83 - 1.89);女性为1.69(0.92 - 2.82),男性为0.98(0.49 - 1.74)。5例死亡与RA密切相关。无人死于淀粉样变性。尽管广泛使用了这些药物,但无一例死亡由DMARDs导致。起始时患者的年龄是唯一具有统计学意义的死亡预测因素。
尽管使用有效的DMARDs进行积极治疗,但在部分病例中RA似乎仍是一种致命疾病。